Michael Rubin
Founder & CEO @ Northpond Ventures
Bethesda, United States
Michael Rubin is a seed investor at Northpond Ventures in Bethesda focused on Health Care and Biotechnology. Michael P. Rubin is based out of Bethesda, Maryland and is the Founder and CEO of Northpond Venture. Michael previously worked at Sands Capital as a Co-Founder and Managing Partner, Sands Capital Ventures. Michael P. Rubin attended the Northcentral University. Michael P. Rubin has received Albert Potts Research Award and Beem Fisher Research Awardin their career.
- Total investments:
- 37
- Last investment:
- Lead investor:
- 49%
Last updated:
For AI agents: llms.txt
Industries Michael Rubin invests in
Stages Michael Rubin invests in
Countries Michael Rubin invests in
Round sizes
Round size
- Seed
- $3M–$20M
- Series A
- $9.5M–$42M
- Series B
- $10M–$32M
Investment Focus
Industry
- Health Care 8 (22%)
- Biotechnology 8 (22%)
- Medical 5 (14%)
- Software 5 (14%)
- Health Diagnostics 5 (14%)
Stage
- Seed 8 (22%)
- Series A 7 (19%)
- Series B 5 (14%)
- Series C 4 (11%)
- Venture - Series Unknown 3 (8%)
Country
- United States 22 (59%)
- Canada 2 (5%)
- Australia 1 (3%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
VieCure
|
VieCure built an engine to turn data into knowledge and take the world’s best thinking to clinicians and patients in real time. They codify the world’s premier cancer information in an engine that considers each patient’s unique needs and creates the most personalized comprehensive care plan. By accessing our evidence-based knowledge, oncologistscan create actionable cancer patient-specific personalized treatment plans that comply with nationally-accepted standards and the latest genomic-based guidelines. | $43M / Venture - Series Unknown / Jan 12, 2026 | |
Cove Soda
|
Cove Soda is a food and beverage company that specializes in kombucha, a fermented tea beverage. Their organic kombucha is made with ingredients to meet the standards of Organic Canada and the NON-GMO Project. This results in a wholesome product that is sustainable and in harmony with their values. They believe it’s important to give back wheneverpossible.Cove Kombucha offers organic loose leaf tea which is low in sugar, organic verified with fermentation for over a month, enabling the consumer to get a beverage full of probiotics that are good for the stomach. The company's mission is to inspire a healthy lifestyle by providing access to healthy (and delicious) beverages for everyone. | $15M / Series A / Nov 03, 2025 | |
Fanable
|
Fanable is a Web3 marketplace specialized in Pokémon, comic books, and collectibles, allowing users to purchase, sell, and engage with their favorite products in both physical and digital forms. | $11.5M / Venture - Series Unknown / Oct 09, 2025 | |
Phia
|
Phia is a company that provides a tool for online shoppers to compare prices and discover better deals across thousands of retailers and resale platforms. It offers a browser extension and a mobile app that include features such as price-comparison, alerts for price changes, and suggestions of similar or used items when an item seems overpriced.Phia draws on data to help users assess whether a listed price is fair, high, or typical. It also curates personalized shopping feeds and editorial picks based on shoppers’ behavior and preferences. The goal is to simplify decision-making for consumers by consolidating options and insights into one interface. | $8M / Seed / Sep 18, 2025 | |
Octave
|
Octave Bioscience is an early-stage molecular diagnostics company focused on neurodegenerative diseases and conditions. The company was co-founded by Melinda Thomas and William Hagstrom in 2013. Octave Bioscience is headquartered in Menlo Park, California, United States. | $35.6M / Series C / Sep 04, 2025 | |
Outcomes4Me
|
Outcomes4Me provides an AI-powered digital platform designed to assist cancer patients in managing their care. The platform integrates clinical guidelines, genomic data, and clinical trial information to offer personalized treatment options. Patients can access features such as symptom tracking, medication management, and tailored clinical trialmatching. Outcomes4Me also facilitates the organization and understanding of medical records, enabling users to make informed decisions in collaboration with their healthcare providers. The platform is developed in collaboration with experts in oncology and aims to support patients throughout their treatment journey. | $21M / Series A / May 29, 2025 | |
W Labs
|
W is a line of men's personal care products that are intended to work harder and smell amazing. W's better-for-you goods are made to last, especially when you need them most. The company was founded to provide men the confidence to succeed in all that they set their minds to. | $11M / Series A / Jul 23, 2024 | |
Bot-It
|
Bot-It is a platform for artificial intelligence that helps consumers and organizations to automate internet chores. | $300K / Angel / Oct 16, 2023 | |
Glove Wrap
|
Glove Wrap is a latex-free, thermoplastic elastomer band with the precise thickness, width, and length required to break in and shape your complete baseball glove while making the ideal pocket. Wrapping your glove with Glove Wrap applies pressure to the glove, reshaping it for easy use. | $50K / Angel / Oct 16, 2023 | |
|
Octave
|
Octave Bioscience is an early-stage molecular diagnostics company focused on neurodegenerative diseases and conditions. The company was co-founded by Melinda Thomas and William Hagstrom in 2013. Octave Bioscience is headquartered in Menlo Park, California, United States. | $30M / Series B / Jul 26, 2023 | |
| See all 37 investments → | |||
Co-Investors
About Northpond Ventures
Northpond Ventures is a science-driven venture capital firm headquartered in Bethesda, Maryland. Our mission is to build a better tomorrow. Our investments are focused on life sciences, technology, and affiliated industries.
Northpond Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Adam Wieschhaus
Director
|
|||
Andrew Lee
Managing Director
|
|||
|
Connor McDermott
Vice President
|
|||
Karthik Bolisetty
Senior Associate
|
|||
|
Michael Rubin
Founder & CEO
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Michael Rubin invest in?
Michael Rubin invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Series A stage. Most of the 37 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Michael Rubin's check size?
Michael Rubin typically joins rounds of $3M–$20M at Seed, $9.5M–$42M at Series A and $10M–$32M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Michael Rubin participates in.
When did Michael Rubin last invest?
The most recent investment recorded for Michael Rubin closed in Jan 2026. Shizune tracks 37 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
